This profile has not been claimed and data may not be accurate.
30th percentile
94th percentile
YC alum turned GP founding Alix Ventures and the world's first TechBio angel syndicate
Credibility
Firm Standing · 100th percentile
- NFX Signal profile confirms Chas Pulido as a recognized investor with connections to top-tier VCs including First Round Capital and SignalFire.
- Active GP and fund manager at Alix Ventures, a venture capital firm he founded and has run since 2020.
- Partner / Principal at Alix Ventures, a recognized early-stage life science VC firm with a public deal record.
- Publicly identified as an angel investor and founder of BIOS Angels, described as the world's first TechBio angel investing syndicate.
Relationship Matrix
Founder score
- 95%Probability of being accurate (95%)Current founder and General Partner of Alix Ventures, an early-stage life science venture capital firm he founded in 2019.
- 90%Probability of being accurate (90%)Y Combinator S18 alum, having founded Pareto Life Sciences through the program.
- 85%Probability of being accurate (85%)Also founded BIOS, a content and community platform for the life science ecosystem, in addition to Alix Ventures.
Investor score
- 95%Probability of being accurate (95%)Active GP and fund manager at Alix Ventures, a venture capital firm he founded and has run since 2020.
- 92%Probability of being accurate (92%)Partner / Principal at Alix Ventures, a recognized early-stage life science VC firm with a public deal record.
- 85%Probability of being accurate (85%)Publicly identified as an angel investor and founder of BIOS Angels, described as the world's first TechBio angel investing syndicate.
- 82%Probability of being accurate (82%)NFX Signal profile confirms Chas Pulido as a recognized investor with connections to top-tier VCs including First Round Capital and SignalFire.
- 80%Probability of being accurate (80%)Has made at least 6 confirmed active investments including Mythic Therapeutics, ELEGEN, STRM.BIO, Strand Therapeutics, 64x Bio, and iORGANBIO.
- 80%Probability of being accurate (80%)Investing experience spanning approximately 6 years, having started at Liquid 2 Ventures before founding Alix Ventures in 2019–2020.
What you likely need
You're a founder-turned-GP building Alix Ventures into the defining early-stage TechBio fund, and the highest-leverage Festival events for you are rooms that accelerate your Fund II LP pipeline, deepen co-investment relationships with a16z and First Round, and elevate the BIOS brand with the right institutional audience. Dinners and roundtables that put you in front of emerging-manager-friendly LPs, life sciences conference organizers, and YC alumni who've crossed into institutional capital will compound fastest. You also benefit from tactical sessions with other syndicate GPs who've formalized SPV structures, so you can scale BIOS Angels without muddying your main fund economics.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- fundraisingA dinner for YC S18 alumni who've crossed into GP or LP roles, focused on warm introductions to institutional LPs actively backing emerging managers with deep life sciences domain expertise for Fund II raises
- introsA co-investment roundtable with deal partners from a16z Bio, First Round, and Foresite Capital to establish earlier deal-flow sharing agreements and strengthen Alix Ventures' syndication reputation ahead of Fund II
- tacticalA tactical dinner for emerging TechBio GPs who've formalized SPV structures and run co-invest syndicates alongside a main fund, to pressure-test the BIOS Angels legal and economics setup
- positioningA roundtable for Top 5 life sciences podcast hosts and TechBio thought leaders to workshop a quarterly 'State of TechBio' report format that doubles as an LP-visibility and deal-sourcing channel for Alix Ventures
- positioningA happy hour for Forbes 30 Under 30 life sciences honorees and JP Morgan Healthcare Conference organizers to trade speaking slot intros and conference positioning strategies for emerging fund managers
- tacticalA dinner for early-stage TechBio and bio-adjacent GPs managing pro-rata rights and follow-on reserve policies across high-conviction portfolio companies like Strand Therapeutics-stage bets
- introsA YC S18 alumni dinner specifically for batch-mates who've raised institutional capital or LP'd into emerging managers, to surface warm introductions for Chas's Fund II raise at Alix Ventures
- fundraisingA working session for community-native fund managers who've converted newsletter audiences and member communities into formal LP pipelines, benchmarking BIOS Commons' 1,000+ members as a Fund II warm funnel